Focal glomerulosclerosis manifested with nephrotic syndrome.
To assess the long-term outcome for nephrotic children with focal glomerulosclerosis, 23 patients were studied. Twenty were male and three female; the mean age at onset was 7.2 +/- 4.0 years. Twenty of the 23 children had focal segmental glomerulosclerosis, and the other 3 showed focal global sclerosis in renal biopsy specimens. Hypertension (11/23) and hematuria (9/23) were frequent clinical features. Glycosuria (4/23) was occasionally noted. Of the patients studied 13 were initial steroid responders and 10, steroid nonresponders. The mean duration of follow-up for the entire group was 4.7 +/- 4.0 years (ranging from 1 to 13.5 years). From the total study group, 13% had renal deaths; 13% had decreased creatinine clearance, but not end-stage renal disease; 35% had persistent proteinuria; and 39% were in remission. None of the three patients with focal global sclerosis developed chronic renal failure. The data suggest that for children with focal glomerulosclerosis, clinical outcome is not too pessimistic. Except for glycosuria, no clinical or morphologic features were predictive of the development of chronic renal failure, in this study.
Tsau
Y K
YK
Chen
C H
CH
Tsai
W S
WS
Sheu
J N
JN
Kuo
P J
PJ
Hsu
H C
HC
D000293:Adolescent; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications*; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000209:etiology; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications*; D011239:Prednisolone / Q000627:therapeutic use
D011239:Prednisolone